Position doing the winning: current wins credited to a standing already held, with more arriving over it
The model's full reasoning — Q1 2016 call → NOWe need to answer YES or NO based on the transcript. The question asks: On this call, when management explains why the company is CURRENTLY winning business, does it credit a STANDING THE COMPANY ALREADY HOLDS — something durable it built, secured, or became BEFORE this period — as the operative cause of wins that are actually happening now, AND does it convey that further business is already arriving over that same standing without a proportional new push? We need to analyze the transcript. The company is Curis, a biotech. They have programs: CUDC-907, CA170, and Erivedge (partnered with Genentech/Roche). The call is about Q1 2016 earnings. Management discusses CUDC-907: Phase 2 trial ongoing, they have completed enrollment in monotherapy arm, they report responses. They mention a retrospective analysis correlating responses with MYC alterations. They designed Phase 2 to target MYC-altered patients. This is about clinical trials, not necessarily "winning business" in a commercial sense. The company is a biotech with no commercial products except Erivedge royalties. Erivedge is commercialized by Genentech/Roche. They mention Roche initiated two clinical studies with Erivedge outside BCC. That's not about winning business. CA170 is about to enter clinic. Not yet. The question is about "winning business" - likely meaning revenue, customers, contracts, etc. In this context, the company's revenue is from royalties on Erivedge. They report revenues of $1.7 million for each quarter, primarily royalty revenues. They don't attribute that to a standing they hold; it's just existing royalties. Management talks about progress in clinical trials, but that's not "winning business" in the sense of customers or orders. The question might be interpreted more broadly: are they crediting an already-held standing (like a drug approval, a partnership, a technology) for current wins (like clinical trial progress, or partnerships)? But the question specifically says "winning business" - real orders, customers, contracts, volumes, or work in the recent period. In biotech, that could be partnerships, licensing deals, or product sales. Here, they have a partnership with Aurigene, but that was from 2015. They mention the collaboration. But they don't say that current wins are due to that standing. The question asks: "does it credit a STANDING THE COMPANY ALREADY HOLDS ...
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| ACGL | Arch Capital Group Ltd. | Q4 2023 | 2024-02-15 | B+ |
| CHT | Chunghwa Telecom Co., Ltd. | Q4 2023 | 2024-01-30 | C |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| SPIR | Spire Global, Inc. | Q1 2023 | 2023-05-10 | B |
| FTHM | Fathom Holdings, Inc. | Q1 2023 | 2023-05-10 | C |
| BXSL | Blackstone Secured Lending Fund | Q1 2023 | 2023-05-10 | A |
| POOL | Pool Corporation | Q4 2022 | 2023-02-16 | C+ |
| EXFY | Expensify, Inc. | Q2 2022 | 2022-08-12 | D |
| HLIO | Helios Technologies, Inc. | Q1 2022 | 2022-05-10 | C |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| GFS | GLOBALFOUNDRIES Inc. | Q3 2021 | 2021-11-30 | A |
| WMB | The Williams Companies, Inc. | Q3 2021 | 2021-11-02 | B |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| ORAN | Orange SA | Q2 2018 | 2018-07-26 | B |
| ROK | Rockwell Automation, Inc. | Q4 2017 | 2017-11-08 | C |
| MKTX | MarketAxess Holdings Inc. | Q3 2017 | 2017-10-25 | C+ |
| LEA | Lear Corporation | Q2 2017 | 2017-07-26 | B+ |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
EXFY · Q2 2022 → YESThe question is about whether management credits a standing the company already holds as the reason they're currently winning business, and that more is arriving over that same standing without a new ...YES The transcript shows management crediting their pre-existing bottom-up adoption model and differentiated platform position (already in place since day one, with SMB focus and unique acquisition mechanics) as the operative cause of current wins. This is evident in statements like the model being "overwhelmingly driving the success of our business" and competitors routing customers to them due to the same standing. Further business is conveyed as already arriving through the same position, with trends continuing and the best quarter ever achieved on that foundation, even as they note additional investments in sales and conferences.
FTHM · Q1 2023 → YESThe question is about whether management credits a standing the company already holds as the reason they're currently winning business, and if more business is arriving over that same standing without...YES The transcript shows management crediting the company's pre-existing low-cost flat-fee model, owned technology, and culture-driven retention as the durable standing already in place that is generating current wins (market share gains, 18% agent growth, 60% of March referrals, and transaction resilience vs. peers). They describe these as flowing directly from that standing rather than fresh effort, while conveying continuation through the referral program's ongoing positive impact and the model's ability to draw more agents without proportional new marketing push.
ORAN · Q2 2018 → YESThe question is about whether management credits a standing the company already holds as the reason they're currently winning business, and that more is arriving over that same standing without a new ...YES The transcript shows management repeatedly tying current wins (net adds, ARPU growth, EBITDA expansion) directly to a pre-existing durable position: the #1 convergent operator status already achieved through prior leadership in fixed/mobile networks and fiber rollout, plus the installed base of 10.